Global practices of meningococcal vaccine use and impact on invasive disease

References

• Epidemics of meningococcal disease. African meningitis belt. Wkly Epidemiol Rec 2001;76(37):282–8.
   Google Scholar
• Broker M, Fantoni S. Meningococcal disease: a review on available vaccines and vaccines in development. Minerva Med. 2007;98(5):575–89.
   PubMedGoogle Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med. 1969;129(6):1385–95.
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969;129(6):1367–84.
   PubMed Web of Science ®Google Scholar
• Gold R, Artenstein MS. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969–70. Bull World Health Organ. 1971;45(3):279–82.
   PubMed Web of Science ®Google Scholar
• Biselli R, Fattorossi A, Matricardi PM, Nisini R, Stroffolini T, D'Amelio R. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine. 1993;11(5):578–81.
   PubMed Web of Science ®Google Scholar
• Greenwood BM, Hassan-King M, Whittle HC. Prevention of secondary cases of meningococcal disease in household contacts by vaccination. Br Med J. 1978;1(6123):1317–9.
   PubMed Web of Science ®Google Scholar
• Rosenstein N, Levine O, Taylor JP, Evans D, Plikaytis BD, Wenger JD, et al. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA. 1998;279(6):435–9.
   PubMed Web of Science ®Google Scholar
• Miller MA, Wenger J, Rosenstein N, Perkins B. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J. 1999;18(12):1051–9.
   PubMed Web of Science ®Google Scholar
• Saliou P, Stoeckel P, Lafaye A, Rey JL, Renaudet J. [Controlled tests of anti-meningococcal polysaccharide A vaccine in the African Sahel area (Upper Volta and Mali)]. Dev Biol Stand. 1978;41:97–108.
   PubMedGoogle Scholar
• Ismail A, Harris S, Granoff D. Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pediatr Infect Dis J. 2004;23(8):748–55.
   PubMed Web of Science ®Google Scholar
• Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181(2):761–4.
   PubMed Web of Science ®Google Scholar
• Shao Z, Li W, Ren J, Liang X, Xu L, Diao B, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet. 2006;367(9508):419–23.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):273.
   PubMedGoogle Scholar
• Deeks ED. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults. BioDrugs. 2010;24(5):287–97.
   PubMed Web of Science ®Google Scholar
• Menactra: a meningococcal conjugate vaccine. Med Lett Drugs Ther. 2005;47(1206):29–31.
   Web of Science ®Google Scholar
• Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol. 2009;16(12):1810–5.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep. 2009;58(37):1042–3.
   PubMedGoogle Scholar
• Lepage P. [Pharmacy clinics. Medication of the month. Meningitec]. Rev Med Liege. 2001;56(2):124–5.
   PubMedGoogle Scholar
• Serogroup C meningococcal conjugate vaccines: new preparations. Effective from age two months. Prescrire Int. 2003;12(64):43–6.
   PubMedGoogle Scholar
• Schondorf I, Banzhoff A, Nicolay U, Diaz-Mitoma F. Overcoming the need for a cold chain with conjugated meningococcal Group C vaccine: a controlled, randomized, double-blind study in toddlers on the safety and immunogenicity of Menjugate, stored at room temperature for 6 months. Vaccine. 2007;25(7):1175–82.
   PubMed Web of Science ®Google Scholar
• Southern J, Borrow R, Andrews N, Morris R, Waight P, Hudson M, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol. 2009;16(2):194–9.
   PubMed Web of Science ®Google Scholar
• Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalen t meningococcal serogroup C vaccine. Clin Vaccine Immunol. 2010;17(1):154–9.
   PubMed Web of Science ®Google Scholar
• EMC. Menitorix. Available from: http://www.medicines.org.uk/EMC/medicine/17189/SPC/Menitorix/#tableOfContents
   Google Scholar
• Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution. Vaccine. 2009;27(Suppl 2):B13–9.
   Google Scholar
• Highlights of Prescribing Information. Available from: http://us.gsk.com/products/assets/us_menhibrix.pdf (accessed 2013November 2).
   Google Scholar
• Gorringe AR, van Alphen L. 16th International Pathogenic Neisseria Conference: recent progress towards effective meningococcal disease vaccines. Hum Vaccin. 2009;5(2):53–6.
   PubMedGoogle Scholar
• Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol. 2010;17(5):840–7.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364(9431):365–7.
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001;357(9251):195–6.
   PubMed Web of Science ®Google Scholar
• Bose A, Coen P, Tully J, Viner R, Booy R. Effectiveness of meningococcal C conjugate vaccine in teenagers in England. Lancet. 2003;361(9358):675–6.
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197(5):737–43.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Borrow R, Findlow J, Holland A, Frankland S, Andrews NJ, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol. 2008;15(11):1694–8.
   PubMed Web of Science ®Google Scholar
• JCVI interim position statement on use of Bexsero meningococcal B vaccine in the UK, July 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/224896/JCVI_interim_statement_on_meningococcal_B_vaccination_for_web.pdf
   Google Scholar
• Goldblatt D, Borrow R, Miller E. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J Infect Dis. 2002;185(3):397–400.
   PubMed Web of Science ®Google Scholar
• Choo S, Zuckerman J, Goilav C, Hatzmann E, Everard J, Finn A. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine. 2000;18(24):2686–92.
   PubMed Web of Science ®Google Scholar
• Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J Infect Dis. 1996;174(6):1360–3.
   PubMed Web of Science ®Google Scholar
• Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA. 1996;275(19):1499–503.
   PubMed Web of Science ®Google Scholar
• Lakshman R, Jones I, Walker D, McMurtrie K, Shaw L, Race G, et al. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child. 2001;85(5):391–7.
   PubMed Web of Science ®Google Scholar
• Bramley JC, Hall T, Finn A, Buttery RB, Elliman D, Lockhart S, et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine. 2001;19(20–22):2924–31.
   PubMed Web of Science ®Google Scholar
• MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: a randomized controlled trial. JAMA. 2000;283(21):2795–801.
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Andrews N, Southern J, Ashton L, Deane S, et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom. J Infect Dis. 2002;186(9):1353–7.
   PubMed Web of Science ®Google Scholar
• Perrett KP, Winter AP, Kibwana E, Jin C, John TM, Yu LM, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999–2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50(12):1601–10.
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis. 2006;194(12):1745–52.
   PubMed Web of Science ®Google Scholar
• Halperin SA, McDonald J, Samson L, Danzig L, Santos G, Izu A, et al. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study. Clin Invest Med. 2002;25(6):243–51.
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Steul KS, Borkowski A, Ceddia F, Ypma E, Knuf M. Two versus three doses of a meningococcal C conjugate vaccine concomitantly administered with a hexavalent DTaP-IPV-HBV/Hib vaccine in healthy infants. Vaccine. 2008;26(18):2242–52.
   PubMed Web of Science ®Google Scholar
• Burrage M, Robinson A, Borrow R, Andrews N, Southern J, Findlow J, et al. Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection. Infect Immun. 2002;70(9):4946–54.
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infect Immun. 2003;71(10):5549–55.
   PubMed Web of Science ®Google Scholar
• Sigurdardottir ST, Davidsdottir K, Arason VA, Jonsdottir O, Laudat F, Gruber WC, et al. Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. Vaccine. 2008;26(33):4178–86.
   PubMed Web of Science ®Google Scholar
• Kinlin LM, Jamieson F, Brown EM, Brown S, Rawte P, Dolman S, et al. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006. Vaccine. 2009;27(11):1735–40.
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Scheifele DW, Le Saux N, Halperin SA, Vaudry W, Tsang R. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J. 2009;28(3):220–4.
   PubMed Web of Science ®Google Scholar
• Cano R, Larrauri A, Mateo S, Alcala B, Salcedo C, Vazquez JA. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Euro Surveill. 2004;9(7):11–5.
   PubMedGoogle Scholar
• Patel MS. Australia's century of meningococcal disease: development and the changing ecology of an accidental pathogen. Med J Aust. 2007;186(3):136–41.
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Schouls LM, van Derende A. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J. 2006;25(1):79–80.
   PubMed Web of Science ®Google Scholar
• Kafetzis DA, Stamboulidis KN, Tzanakaki G, Kourea Kremastinou J, Skevaki CL, Konstantopoulos A, et al. Meningococcal group C disease in Greece during 1993–2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin Microbiol Infect. 2007;13(5):550–2.
   PubMed Web of Science ®Google Scholar
• Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(Suppl 2):B20–9.
   Google Scholar
• Meningococcal: questions and answers information about the disease and vaccines. Available from: http://www.immunize.org/catg.d/p4210.pdf (accessed 2013 November 2).
   Google Scholar
• Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Preziosi MP, et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine. 2007;25(Suppl 1):A101–7.
   Google Scholar
• Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991;14(2):195–207; discussion 8–10.
   PubMedGoogle Scholar
• Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, et al. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16–24 months. Pediatr Infect Dis J. 2007;26(4):345–50.
   PubMed Web of Science ®Google Scholar
• Wong SH, Lennon DR, Jackson CM, Stewart JM, Reid S, Ypma E, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J. 2009;28(5):385–90.
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–37.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein -based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490–5.
   PubMed Web of Science ®Google Scholar
• Guidelines for the early clinical and public health management of meningococcal disease in Australia – revised edition 2007. Communicable Diseases Network Australia; 2007. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-other-mening-2007.htm
   Google Scholar
• Frosi G, Biolchi A, Sapio ML, Rigat F, Gilchrist S, Lucidarme J, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–74.
   PubMed Web of Science ®Google Scholar
• Bjune G, Høiby EA, Grønnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338(8775):1093–6.
   PubMed Web of Science ®Google Scholar
• Delbos V, Lemée L, Bénichou J, Berthelot G, Deghmane AE, Leroy JP, et al. Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine. 2013;31(40):4416–4420.
   PubMed Web of Science ®Google Scholar
• Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6–8 October, 2000. Vaccine. 2001;19(31):4347–56.
   PubMedGoogle Scholar
• Whalen CM, Hockin JC, Ryan A, Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidis. JAMA. 1995;273(5):390–4.
   PubMed Web of Science ®Google Scholar
• Tao H, Li YN, Wu CH. [Study on safety and immunogenicity of group A/C meningococcal polysaccharide conjugate vaccine]. Zhongguo Ji Hua Mian Yi. 2009;15(6):531–5.
   PubMedGoogle Scholar
• Climent Y, Yero D, Martinez I, Martin A, Jolley KA, Sotolongo F, et al. Clonal distribution of disease-associated and healthy carrier isolates of Neisseria meningitidis between 1983 and 2005 in Cuba. J Clin Microbiol. 2010;48(3):802–10.
   PubMed Web of Science ®Google Scholar
• Dickinson FO, Perez AE. Bacterial meningitis in children and adolescents: an observational study based on the national surveillance system. BMC Infect Dis. 2005;5:103.
   PubMed Web of Science ®Google Scholar
• Nakhla I, Frenck RW Jr, Teleb NA, El Oun S, Sultan Y, Mansour H, et al. The changing epidemiology of meningococcal meningitis after introduction of bivalent A/C polysaccharide vaccine into school-based vaccination programs in Egypt. Vaccine. 2005;23(25):3288–93.
   PubMed Web of Science ®Google Scholar
• Childhood Vaccination Schedule [database on the Internet]. Haut conseil de la santé publique. Available from: http://www.euvac.net/graphics/euvac/vaccination/france.html
   Google Scholar
• Meningococcal vaccination (MenC) overview in European countries [database on the Internet]. Available from: http://www.euvac.net/graphics/euvac/vaccination/menc.html
   Google Scholar
• Salleras L, Dominguez A, Cardenosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine. 2003;21(7–8):729–33.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31(1):101–7.
   PubMed Web of Science ®Google Scholar
• Booy R, Jelfs J, El Bashir H, Nissen MD. Impact of meningococcal C conjugate vaccine use in Australia. Med J Aust. 2007;186(3):108–9.
   PubMed Web of Science ®Google Scholar
• Ameratunga S, Macmillan A, Stewart J, Scott D, Mulholland K, Crengle S. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy. Vaccine. 2005;23(17–18):2231–4.
   PubMed Web of Science ®Google Scholar
• Baker MG, Martin DR, Kieft CE, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000. J Paediatr Child Health. 2001;37(5):S13–9.
   Google Scholar
• De Queiros L, Castro L, Ferreira MC, Goncalves G. [Acceptance of the new conjugate vaccines. Meningococcal and pneumococcal vaccines, in the cohort born in 1999, in the North Region of Portugal]. Acta Med Port. 2004;17(1):49–53.
   PubMedGoogle Scholar
• Baltimore RS. Recent trends in meningococcal epidemiology and current vaccine recommendations. Curr Opin Pediatr. 2006;18(1):58–63.
   PubMed Web of Science ®Google Scholar
• Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev. 2007;31(1):27–36.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. 2010. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2009. [database on the Internet].
   Google Scholar
• Colombini A, Bationo F, Zongo S, Ouattara F, Badolo O, Jaillard P, et al. Costs for households and community perception of meningitis epidemics in burkina faso. Clin Infect Dis. 2009;49(10):1520–5.
   PubMed Web of Science ®Google Scholar
• Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics. 2005;23(9):855–74.
   PubMed Web of Science ®Google Scholar
• Guerin PJ, Naess LM, Fogg C, Rosenqvist E, Pinoges L, Bajunirwe F, et al. Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLoS Negl Trop Dis. 2008;2(12):e342.
   Google Scholar